Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriFol is a branded nutraceutical combination product marketed by Sugen Pharma, primarily indicated for pregnancy support and the prevention of fetal deformities such as neural tube defects (NTDs). The formulation typically contains the biologically active forms of three essential B-vitamins: L-methylfolate (Vitamin B9), methylcobalamin (Vitamin B12), and pyridoxal 5-phosphate (Vitamin B6). Unlike synthetic folic acid, L-methylfolate does not require conversion by the enzyme methylenetetrahydrofolate reductase (MTHFR), making it particularly effective for individuals with MTHFR genetic polymorphisms. These components work synergistically to regulate homocysteine levels and support DNA synthesis and methylation, which are critical processes during preconception and pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TriFol.